Comparison of the Diagnostic Performances of ACR-TIRADS, EU-TIRADS, and Bethesda Classifications in Predicting Malignancy in Thyroid Nodules
The European Research Journal · 06.11.2026 · 1-10
DOI: 10.18621/eurj.1425 ↗Kurz gefasst
Fachartikel in der Zeitschrift The European Research Journal, online erschienen am 06.11.2026. Verfasst von Mehmet Tonkaz und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To compare the diagnostic performance of ultrasound-based risk stratification systems (ACR-TIRADS and EU-TIRADS) with the Bethesda classification in predicting thyroid nodule malignancy.
Methods
This prospective cohort study included consecutive patients undergoing ultrasound-guided fine-needle aspiration biopsy between January 3 and December 30, 2024. Among 239 enrolled patients, 154 with histopathological confirmation following thyroidectomy were analyzed. Nodules were classified using ACR-TIRADS and EU-TIRADS criteria; cytological findings were categorized via the Bethesda system. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis, and independent predictors of malignancy were identified through logistic regression.
Results
Among 154 operated patients, histopathology confirmed malignancy in 40.3% of nodules. Malignancy rates increased significantly with advancing categories across all 3 systems (P < .001). Individual performances were moderate and statistically similar: ACR-TIRADS (area under the curve [AUC], 0.72), EU-TIRADS (AUC, 0.71), and Bethesda (AUC, 0.72) (ACR-TIRADS vs EU-TIRADS, DeLong test, P = .70). Accuracy improved when all systems were combined (AUC, 0.78). On multivariable analysis, only Bethesda remained an independent predictor of malignancy (odds ratio, 1.96; P < .001). In the cytologically indeterminate Bethesda III–IV subgroup (n = 73), both TIRADS systems demonstrated high sensitivity (85.2%) but low specificity (37.0% to 39.1%; AUC range, 0.65 to 0.68).
Conclusion
Bethesda cytology was the strongest independent predictor of thyroid malignancy. ACR-TIRADS and EU-TIRADS provide valuable complementary roles in determining biopsy indications, particularly for cytologically indeterminate nodules. Combined assessment optimizes diagnostic accuracy and supports clinical decision-making.
Zitieren
APA
Tonkaz, M., Pınar, E., Tonkaz, G., Erkal, D., Aslan, S., Bekci, T., Sengul, I., Aksoy, I., & Sengul, D. (2026). Comparison of the Diagnostic Performances of ACR-TIRADS, EU-TIRADS, and Bethesda Classifications in Predicting Malignancy in Thyroid Nodules. The European Research Journal, 1-10. https://doi.org/10.18621/eurj.1425
Vancouver
Tonkaz M, Pınar E, Tonkaz G, Erkal D, Aslan S, Bekci T, et al. Comparison of the Diagnostic Performances of ACR-TIRADS, EU-TIRADS, and Bethesda Classifications in Predicting Malignancy in Thyroid Nodules. The European Research Journal. 2026:1-10. doi:10.18621/eurj.1425
BibTeX
@article{Tonkaz2026,
author = {Tonkaz, Mehmet and Pınar, Esra and Tonkaz, Gökhan and Erkal, Duygu and Aslan, Serdar and Bekci, Tumay and Sengul, Ilker and Aksoy, Iskender and Sengul, Demet},
title = {Comparison of the Diagnostic Performances of ACR-TIRADS, EU-TIRADS, and Bethesda Classifications in Predicting Malignancy in Thyroid Nodules},
journal = {The European Research Journal},
year = {2026},
pages = {1--10},
doi = {10.18621/eurj.1425}
}
EUVIMED